Search

Copyright of Sakarya Journal of Economics / Sakarya Iktisat Dergisi is the property of Sakarya Journal of Economics / Sakarya Iktisat Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Metal contamination constitutes a major source of pollution globally. Many recent studies emphasized the need to develop cheap and green technologies for the remediation or reclamation of environmental matrices contaminated by heavy metals. In this context, fungi are versatile organisms that can be exploited for bioremediation activities. In our work, we tested silver (Ag) bioaccumulation capabilities of three microfungal strains (Aspergillus alliaceusThom & Church,Trichoderma harzianumRifai,Clonostachys rosea(Link) Schroers, Samuels, Seifert & W. Gams) isolated from a silver polluted site. The aim was to select silver tolerant native strains and test their potential silver uptake. Among the three species tested,T. harzianumwas the most efficient strain to tolerate and accumulate silver, showing an uptake capability of 153 mg L−1taken at the Ag concentration of 330 mg L−1. Our study highlights the potential use of native microfungi spontaneously growing in sulphide-rich waste rock dumps, for silver bioaccumulation and bioremediation. [ABSTRACT FROM AUTHOR]

Background: The current trial assessed whether the addition of cisplatin and capecitabine to the nab-paclitaxel-gemcitabine backbone is feasible and active against borderline and locally advanced pancreatic adenocarcinoma (PDAC)., Method: Fifty-four chemo-naive patients, aged between 18 and 75 years, with a pathological diagnosis of locally advanced or borderline resectable PDAC were randomised to receive either nab-paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26) or nab-paclitaxel followed by gemcitabine (AG; arm B; N = 28). The primary end-point was the tumour resection rate. If at least four such resections were performed, the treatment was considered as active. The secondary end-points were progression-free survival (PFS), overall survival (OS), Response Evaluation Criteria in Solid Tumours response rate, Hartman's pathologic response, carbohydrate antigen 19.9 response rate and toxicity., Results: Eight patients (31%) in the PAXG arm and nine (32%) in the AG arm underwent resection. PFS at 1-year was 58% in arm A and 39% in arm B. OS at 18-month was 69% in arm A and 54% in arm B., Conclusions: In this phase II study, the addition of cisplatin and capecitabine to the AG backbone was feasible and yielded promising results in terms of disease control without detrimental impact on tolerability. The approach warrants further investigation in a phase III study., Trial Registration: NCT01730222., (Copyright © 2018 Elsevier Ltd. All rights reserved.)